Biomedical subjects

Y Satomi

Publications and source records attributed to Y Satomi.

At least 109 records · Page 6Linked to original sources

PubMed1983

[Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide].

Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog. Preliminary studies performed in our hospitals demonstrate the releasing effect of Ifosfamide for persistent pain caused by metastases of the prostatic cancer at various regions. Ifosfamide was given 2 grams a day intravenously with hydration and alkalization for consecutive 5 days. The regimen was performed every 3 or 4 weeks. Pain has disappeared in 7 of 10 cases within 2 or 3 courses. Pain of other 3 cases has also greatly reduced. The effective rate for the primary lesion of the prostatic carcinoma in stage C and D is 30.7%. Side effects were nausea, vomiting, hair loss and leukopenia.

Aged↗

PubMed1983

[Pulmonary metastasis of renal cell carcinoma].

I treated 116 patients with pulmonary metastasis from renal cell carcinoma (312 cases). My experience with anticancer chemotherapy indicates that complete response was elicited in 1/15, 0/14, 0/10, 1/6, 0/5 and 0/20 of cases receiving Ft-207, CCNU, vinblastine, adriamycin, ifosfamide and MFC, respectively. Progesterone therapy produced complete response in one of 60 and partial response in 2 of 60. Interferon therapy was effective in 2 of 10 cases. Surgical removal of pulmonary metastatic lesion was done in only 6% (7/116) of cases, which was worth trying especially in low grade cases. The 3 and 5 year survival Jap. rates for the entire 116 cases were 20% and 6%, respectively.

Adenocarcinoma↗

PubMed1982

Postoperative prophylactic use of progesterone in renal cell carcinoma.

Medroxyprogesterone acetate has been used prophylactically in 35 patients with stages I and IIIA renal cell carcinoma who had undergone radical nephrectomy. Metastasis was noted in 26 per cent (9 of 35) of the patients who had received the drug and in 44 per cent (20 of 45) of those who had not (controls). The incidence of metastasis in patients who had undergone nephrectomy more than 3 years previously was 10 per cent (3 of 31) for patients who received medroxyprogesterone acetate and 35 per cent (15 of 43) for the control group, the difference being statistically significant. Prognosis tended to be better in patients who had received medroxyprogesterone acetate than in the controls, and relative 3 and 5-year survival rates being 99.3 and 87.2 per cent, respectively, in the former group, and 86.8 and 75.0 per cent, respectively, in the latter group. There was no significant difference between these 2 groups. However, it may be concluded that prophylactic medroxyprogesterone acetate seems to be beneficial in the prevention of postoperative metastasis of renal cell carcinoma.

Adenocarcinoma↗

PubMed1982